Menke J G, Borkowski J A, Bierilo K K, MacNeil T, Derrick A W, Schneck K A, Ransom R W, Strader C D, Linemeyer D L, Hess J F
Merck Research Laboratories, Department of Molecular Pharmacology and Biochemistry, Rahway, New Jersey 07065.
J Biol Chem. 1994 Aug 26;269(34):21583-6.
A cDNA clone encoding a human B1 bradykinin receptor was isolated from a human embryonic lung fibroblast cDNA library by expression cloning. The photoprotein aequorin was utilized as an indicator of the ability of the B1 receptor agonist [des-Arg10]kallidin to mediate Ca2+ mobilization in Xenopus laevis oocytes injected with RNA. A clone was isolated with a 1307-nucleotide insert which contains an open reading frame encoding a 353-amino acid protein with the characteristics of a G-protein-coupled receptor. The amino acid sequence of the B1 bradykinin receptor is 36% identical to the amino acid sequence of the B2 bradykinin receptor. The cloned B1 bradykinin receptor expressed in mammalian cells exhibits high affinity binding for 3H-labeled [des-Arg10]kallidin and low affinity for bradykinin. The B1 receptor antagonist [des-Arg10,Leu9]kallidin effectively displaces 3H-labeled [des-Arg10]kallidin from the cloned receptor, whereas the B2 receptor antagonist Hoe-140 (D-Arg0-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin, where Thi is L-[3-(2-thienyl)alanyl], Tic is D-(1,2,3,4-tetrahydroisoquinolin-3-yl-carbonyl), and Oic is L-[(3aS, 7aS)-octahydroindol-2-yl-carbonyl]) does not. Therefore, the expressed receptor has the pharmacological characteristics of the B1 receptor subtype. The availability of both the cloned human B1 and B2 bradykinin receptors should allow the elucidation of the relative contributions of these two receptor subtypes in acute and chronic inflammatory processes.
通过表达克隆从人胚胎肺成纤维细胞cDNA文库中分离出一个编码人B1缓激肽受体的cDNA克隆。发光蛋白水母发光蛋白被用作B1受体激动剂[去-精氨酸10]胰激肽在注射了RNA的非洲爪蟾卵母细胞中介导Ca2+动员能力的指示剂。分离出一个带有1307个核苷酸插入片段的克隆,该片段包含一个开放阅读框,编码一个具有G蛋白偶联受体特征的353个氨基酸的蛋白质。B1缓激肽受体的氨基酸序列与B2缓激肽受体的氨基酸序列有36%的同一性。在哺乳动物细胞中表达的克隆B1缓激肽受体对3H标记的[去-精氨酸10]胰激肽表现出高亲和力结合,对缓激肽表现出低亲和力。B1受体拮抗剂[去-精氨酸10,亮氨酸9]胰激肽能有效地从克隆受体上取代3H标记的[去-精氨酸10]胰激肽,而B2受体拮抗剂Hoe-140(D-精氨酸0-[Hyp3,Thi5,D-Tic7,Oic8]缓激肽,其中Thi是L-[3-(2-噻吩基)丙氨酰基],Tic是D-(1,2,3,4-四氢异喹啉-3-基-羰基),Oic是L-[(3aS,7aS)-八氢吲哚-2-基-羰基])则不能。因此,所表达的受体具有B1受体亚型的药理学特征。克隆的人B1和B2缓激肽受体的可得性应有助于阐明这两种受体亚型在急性和慢性炎症过程中的相对作用。